Mauna Kea Technologies   Report issue

For profit
Founded: Paris France (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2016
NCT02878083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Other Trials (2)

adalimumab (humira) (1 trial)

vedolizumab (entyvio) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 2